Cascade screening in familial hypercholesterolemia: Advancing forward

Journal of Atherosclerosis and Thrombosis

Volumn 22, Issue 9, 2015, Pages 869-880

  Santos, Raul D ^a   Frauches, Thiago S ^b   Chacra, Ana P M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Hemostasis and Thrombosis Laboratory   (Brazil)

Author keywords

Cascade screening; Cholesterol; Clinical cascade; Familial hypercholesterolemia; Genetic cascade

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

BIBLIOGRAPHIC DATABASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; FAMILIAL HYPERCHOLESTEROLEMIA; GENE SEQUENCE; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PATHOGENICITY; POPULATION GENETIC PARAMETERS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; SYSTEMATIC REVIEW (TOPIC); ADOLESCENT; ADULT; BLOOD; CARDIOLOGY; CARDIOVASCULAR DISEASE; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; FACTUAL DATABASE; FAMILY HEALTH; FEMALE; GENETICS; HEALTH CARE POLICY; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE II; INFANT; MALE; MANPOWER; MASS SCREENING; MOLECULAR PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; CARDIOLOGY; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; CHOLESTEROL, LDL; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; FAMILY HEALTH; FEMALE; HEALTH POLICY; HUMANS; HYPERLIPIDEMIAS; HYPERLIPOPROTEINEMIA TYPE II; INFANT; MALE; MASS SCREENING; PATHOLOGY, MOLECULAR; RISK FACTORS; YOUNG ADULT;

EID: 84941657356     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.31237     Document Type: Review

References (107)

1. Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, Nohara A, Bujo H, Yokote K, Wakatsuki A, Ishibashi S, Yamashita S: Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb, 2012; 19: 1043-1060
2. Austin MA, Hutter CM, Zimmern RL, Humphries SE: Genetic causes of monogenic heterozygous familial hypercholesterolaemia: a HuGE prevalence review. Am J Epidemiol, 2004; 160: 407-420
3. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG: Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab, 2012; 97: 3956-3964
4. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel: Familial hypercholesterolaemia is under diagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease Consensus Statement of the European Atherosclerosis Society. Eur Heart J, 2013; 34, 3478-3490
5. Modell SM, Kardia SL, Citrin: Stakeholder consultation insights on the future of genomics at the clinical-public health interface. Transl Res, 2014; 163: 466-477
6. George R, Kovak K, Cox SL: Aligning Policy to Promote Cascade Genetic Screening for Prevention and Early Diagnosis of Heritable Diseases. J Genet Couns, 2015; 24: 388-399
7. Centers for Disease Control and Prevention, Office of Public Health Genomics: Genomic Tests and Family History by Levels of Evidence, 2013 Retrieved from http://www.cdc.gov/genomics/gtesting/tier.htm
8. Bowen MS, Kolor K, Dotson WD, Ned RM, Khoury MJ: Public health action in genomics is now needed beyond newborn screening. Pub Heal Genom, 2012; 15, 327-334
9. Page MM, Stefanutti C, Sniderman A, Watts GF: Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/ kexin type 9. Clin Sci (Lond), 2015; 129: 63-79
10. Bell DA, Pang J, Burrows S, Bates TR, van Bockxmeer FM, Hooper AJ, O’Leary P, Burnett JR, Watts GF: Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience. Atherosclerosis, 2015; 239: 93-100
11. Jannes CE, Santos RD, de Souza Silva PR, Turolla L, Gagliardi AC, Marsiglia JD, Chacra AP, Miname MH, Rocha VZ, Filho WS, Krieger JE, Pereira AC: Familial hypercholesterolemia in Brazil: cascade screening program, clinical and genetic aspects. Atherosclerosis, 2015; 238: 101-107
12. Hu M, Lan W, Lam CW, Mak YT, Pang CP, Tomlinson B: Heterozygous familial hypercholesterolemia in Hong Kong Chinese. Study of 252 cases. Int J Cardiol, 2013; 167: 762-767
13. Fouchier SW, Kastelein JJ, Defesche JC: Update of the molecular basis of familial hypercholesterolemia in The Netherlands. Hum Mutat, 2005; 26: 550-556
14. Bourbon M, Alves AC, Medeiros AM, Silva S, Soutar AK; Investigators of Portuguese FH Study: Familial hypercholesterolaemia in Portugal. Atherosclerosis, 2008; 196: 633-642
15. Palacios L, Grandoso L, Cuevas N, Olano-Martín E, Martinez A, Tejedor D, Stef M: Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis, 2012; 221: 137-142
16. Hadfield SG, Horara S, Starr BJ, Yazdgerdi S, Marks D, Bhatnagar D, Cramb R, Egan S, Everdell R, Ferns G, Jones A, Marenah CB, Marples J, Prinsloo P, Sneyd A, Stewart MF, Sandle L, Wang T, Watson MS, Humphries SE; Steering Group for the Department of Health Familial Hypercholesterolaemia Cascade Testing Audit Project: Family tracing to identify patients with familial hypercholesterolaemia: the second audit of the Department of Health Familial Hypercholesterolaemia Cascade Testing Project. Ann Clin Biochem, 2009; 46: 24-32
17. Marks D, Thorogood M, Neil SM, Humphries SE, Neil HA: Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes. J Med Screen, 2006; 13: 156-159
18. O’Kane MJ, Menown IB, Graham I, Maher V, Tomkin G, Nicholls P, Graham C: The detection of heterozygous familial hypercholesterolemia in Ireland. Adv Ther, 2012; 29: 456-463
19. Watts GF, Sullivan DR, Poplawski N, van Bockxmeer F, Hamilton-Craig I, Clifton PM, O’Brien R, Bishop W, George P, Barter PJ, Bates T, Burnett JR, Coakley J, Davidson P, Emery J, Martin A, Farid W, Freeman L, Geelhoed E, Juniper A, Kidd A, Kostner K, Krass I, Livingston M, Maxwell S, O’Leary P, Owaimrin A, Redgrave TG, Reid N, Southwell L, Suthers G, Tonkin A, Towler S, Trent R; Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl, 2011; 12: 221-263
20. Hadfield SG, Humphries SE: Implementation of cascade testing for the detection of familial hypercholesterolaemia. Curr Opin Lipidol, 2005; 16: 428-433
21. Agard A, Bolmsjo I, Hermeren G, Wahlstom J: Familial hypercholesterolemia: ethical, practical and psychological problems from the perspectives of patients. Patient Educ Couns, 2005; 57: 162-167
22. McCrindle BW, Chair MPH, Urbina EM, Dennison BA, Jacobson MS, Marc S, Steinberger J, Rocchini AP, Hayman LL, Daniels SR: Drug therapy of high risk lipid abnormalities in children and adolescents. Circulation, 2007; 115: 1-20
23. Newson AJ, Humphries SE: Cascade testing in familial hypercholesterolaemia: How should family members be contacted ? Eur J Hum Genet, 2005; 13: 401-408
24. Suthers GK, Armstrong J, McCormack J, Trott D: Letting the family know: balancing ethics and effectiveness when notifying relatives about genetic testing for a familial disorder. J Med Genet, 2006; 43: 665-670
25. Crotser, C & Dickerson, S: Learning about a twist in the road: perspectives of at-risk relatives learning of potential for cancer. Onc Nurs For, 2010; 37: 723-733
26. Human Genetics Society of Australasia: Position statement: pre-symptomatic and predictive testing in children and young people, 2008 27. Human Genetics Society of Australasia: Process of genetic counseling, 2008
27. Jenkins N, Lawton J, Douglas M, Walker S, Finnie R, Porteous M, Hallowell N: How do index patients participating in genetic screening programmes for familial hypercholesterolemia FH. interpret their DNA results? A UK-based qualitative interview study. Patient Educ Couns, 2013; 90: 372-377
28. Ademi Z, Watts GF, Juniper A, Liew D: A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int J Cardiol. 2013; 167: 2391-2396
29. Chen CX, Hay JW: Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States. Int J Cardiol, 2015; 181: 417-424
30. Gumbs PD, Verschuren MWM, Mantel-Teeuwisse AK, De Wit AG, De Boer A, Klungel OH: Economic evaluations of cholesterol-lowering drugs: a critical and systematic review. Pharmacoeconomics, 2007; 25: 187-199
31. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A: A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess, 2007; 11
32. HEART UK: Saving lives, saving families: the health, social and economic advantagesWatahypercholesterolemia FH. interpret their DNA results? A UK-based qualitative interview study. Patient Educ Couns, 2013; 90: 372-377
33. Ademi Z, Watts GF, Juniper A, Liew D: A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int J Cardiol. 2013; 167: 2391-2396
34. Chen CX, Hay JW: Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States. Int J Cardiol, 2015; 181: 417-424
35. Gumbs PD, Verschuren MWM, Mantel-Teeuwisse AK, De Wit AG, De Boer A, Klungel OH: Economic evaluations of cholesterol-lowering drugs: a critical and systematic review. Pharmacoeconomics, 2007; 25: 187-199
36. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A: A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess, 2007; 11
37. HEART UK: Saving lives, saving families: the health, social and economic advantages of detecting and treating familial hypercholesterolaemia (FH). 2012; http://heartuk.org.uk/files/uploads/documents/HUK_HealthEconomics_FINAL2012_2702.pdf
38. Marang-van de Mheen PJ, Ten Asbroek AHA, Bonneux L, Bonsel GJ, Klazinga NS: Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands. Eur Heart J, 2002; 23: 1922-1930
39. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HAW: Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ, 2002; 324: 1303-1306
40. Marks D, Thorogood M, Neil HAW, Wonderling D, Humphries SE: Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening. J Public Health Med, 2003; 25: 47-52
41. Wonderling D, Umans-Eckenhausen MAW, Marks D, Defesche JC, Kastelein JJP, Thorogood M: Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin Vasc Med, 2004; 4: 97-104
42. Oliva J, Lopez-Bastida J, Moreno SG, Mata P, Alonso R: Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia. Rev Esp Cardiol, 2009; 62: 57-65
43. D’Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PWF: Primary and subsequent coronary risk appraisal: New results from the Framingham Study. Am Heart J, 2000; 139: 272-281
44. Avis HJ, Kusters DM, Vissers MN, Huijgen R, Janssen TH, Wiegman A, Kindt I, Kastelein JJ, Wijburg FA, Hutten BA: Follow-up of children diagnosed with familial hypercholesterolemia in a national genetic screening program. J Pediatr, 2012; 161: 99-103
45. Stef MA, Palacios L, Olano-MartÃ-n E, Foe-A-Man C, van de Kerkhof L, Klaaijsen LN, Molano A, Schuurman EJ, Tejedor D, Defesche JC: A DNA microarray for the detection of point mutations and copy number variation causing familial hypercholesterolemia in Europe. J Mol Diagn, 2013; (3): 362-372
46. Wald DS, Bestwick JP, Wald NJ: Familial hypercholesterolaemia: screening needs a fresh approach. BMJ, 2007; 335: 1007-1008
47. Hadfield GS, Humphries SE: Familial hypercholesterolaemia: Cascade testing is tried and tested and cost effective. BMJ, 2007; 335: 683
48. Morris JK, Wald DS, Wald NJ: The evaluation of cascade testing for familial hypercholesterolemia. Am J Med Genet A, 2012; 158A: 78-84
49. Qureshi N, Humphries SE, Seed M, Rowlands P, Minhas R, NICE Guideline Development Group: Identification and management of familial hypercholesterolaemia: what does it mean to primary care ? Br J Gen Pract, 2009; 59: 773-776
50. Hardcastle SJ, Legge E, Laundy CS, Egan SJ, French R, Watts GF, Hagger MS: Patients’ perceptions and experiences of familial hypercholesterolemia, cascade genetic screening and treatment. Int J Behav Med, 2015; 22: 92-100
51. Bell DA, Hooper AJ, Edwards G, Southwell L, Pang J, van Bockxmeer FM, Watts GF, Burnett JR: Detecting familial hypercholesterolaemia in the community: impact of a telephone call from a chemical pathologist to the requesting general practitioner. Atherosclerosis, 2014; 234: 469-472
52. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ: Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet, 2001; 357: 165-168
53. Maxwell SJ, Molster CM, Poke SJ, O’Leary P: Communicating familial hypercholesterolemia genetic information within families. Genet Test Mol Biomarkers, 2009; 13: 301-306
54. Hallowell N, Jenkins N, Douglas M, Walker S, Finnie R, Porteous M, Lawton J: Patients’ experiences and views of cascade screening for familial hypercholesterolemia (FH): a qualitative study. J Community Genet, 2011; 2: 249-257
55. Allison M: Communicating Risk With Relatives in a Familial Hypercholesterolemia Cascade Screening Program: A Summary of the Evidence. J Cardiovasc Nurs, 2015; 30: E1-E12
56. Homsma SJ, Huijgen R, Middeldorp S, Sijbrands EJ, Kastelein JJ: Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance. Eur J Hum Genet, 2008; 16: 14-17
57. Homsma SJ, Lansberg PJ, Kastelein JJ: Genetic screening of patients with familial hypercholesterolemia and insurability for life insurance policies and disability cover policies [in Dutch]. Ned Tijdschr Geneeskd, 2004; 148: 493-496
58. Huijgen R, Homsma SJ, Hutten BA, Kindt I, Vissers MN, Kastelein JJ, van Rijckevorsel JL: Improved access to life insurance after genetic diagnosis of familial hypercholesterolaemia: cross-sectional postal questionnaire study. Eur J Hum Genet, 2012; 20: 722-728
59. Harada-Shiba M, Arai H, Okamura T, Yokote K, Oikawa S, Nohara A, Okada T, Ohta T, Bujo H, Wata-nabe M, Wakatsuki A, Yamashita S: Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb, 2012; 19: 1019-1026
60. Artieda M, Cenarro A, Junquera C, Lasierra P, Martínez- Lorenzo MJ, Pocoví M, Civeira F: Tendon xanthomas in familial hypercholesterolemia are associated with a differential inflammatory response of macrophages to oxidized LDL. FEBS Lett, 2005; 579: 4503-4512
61. Starr B, Hadfield SG, Hutten BA, Lansberg PJ, Leren TP, Damgaard D, Neil HA, Humphries SE: Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem LabMed, 2008; 46: 791-803
62. Daniels SR, Greer FR, The Committee on Nutrition: Lipid screening and cardiovascular health in childhood. Pediatrics, 2008; 122: 198-208
63. Descamps OS, Tenoutasse S, Stephenne X, Gies I, Beauloye V, Lebrethon MC, De Beaufort C, De Waele K, Scheen A, Rietzschel E, Mangano A, Panier JP, Ducobu J, Langlois M, Balligand JL, Legat P, Blaton V, Muls E, Van Gaal L, Sokal E, Rooman R, Carpentier Y, De Backer G, Heller FR: Management of familal hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a parent organization. Atherosclerosis, 2011; 218: 272-280
64. Primary Panel, Genest J, Hegele RA, Bergeron J, Brophy J, Carpentier A, Couture P, Davignon J, Dufour R, Frohlich J, Gaudet D, Gupta M, Krisnamoorthy P, Mancini J, McCrindle B, Raggi P, Ruel I, St-Pierre J: Canadian Cardiovascular Society position statement on familial hypercholesterolemia. Can J Cardiol, 2014; 30: 1471-1481
65. Al-Rasadi K, Al-Waili K, Al-Sabti HA, Al-Hinai A, Al- Hashmi K, Al-Zakwani I, Banerjee Y: Criteria for Diagnosis of Familial Hypercholesterolemia: A Comprehensive Analysis of the Different Guidelines, Appraising their Suitability in the Omani Arab Population. Oman Med J, 2014; 29: 85-91
66. Thomas ER, Atanur SS, Norsworthy PJ, Encheva V, Snijders AP, Game L, Vandrovcova J, Siddiq A, Seed M, Soutar AK, Aitman TJ: Identification and biochemical analysis of a novel APOB mutation that causes autosomal dominant hypercholesterolemia. Mol Genet Gen Med, 2013; 1: 155-161
67. Kindt I, Huijgen R, Boekel M, van der Gaag KJ, Defesche JC, Kastelein JJ, de Knijff P: Quality assessment of the genetic test for familial hypercholesterolemia in the Netherlands. Cholesterol, 2013; 2013: 531-658
68. Wilson C: Targeting cascade screening in familial hypercholesterolaemia. Nat Rev Endocrinol, 2013; 9: 254
69. Huijgen R, Kindt I, Defesche JC, Kastelein JJ: Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29,365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants. Eur Heart J, 2012; 33: 2325-2330
70. Humphries S, Pedersen K: GPs have key role in detecting familial hypercholesterolaemia. Practitioner, 2011; 255: 25-27, 3
71. Medeiros AM, Alves AC, Francisco V, Bourbon M; investigators of the Portuguese FH Study: Update of the Portuguese Familial Hypercholesterolaemia Study. Atherosclerosis, 2010; 212: 553-558
72. Huijgen R, Kindt I, Fouchier SW, Defesche JC, Hutten BA, Kastelein JJ, Vissers MN: Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia. Hum Mutat, 2010; 31: 752-760
73. Liyanage KE, Hooper AJ, Defesche JC, Burnett JR, van Bockxmeer FM: High-resolution melting analysis for detection of familial ligand-defective apolipoprotein B-100 mutations. Ann Clin Biochem, 2008; 45: 170-176
74. Benito-Vicente, A, Alves, AC, Etxebarria, A, Medeiros, AM, Martin, C, Bourbon, M: The importance of an integrated analysis of clinical, molecular, and functional data for the genetic diagnosis of familial hypercholesterolemia. Genet Med, 2015 [Epub ahead of print]
75. Taylor A, Wang D, Patel K, Whittall R, Wood G, Farrer M, Neely RD, Fairgrieve S, Nair D, Barbir M, Jones JL, Egan S, Everdale R, Lolin Y, Hughes E, Cooper JA, Hadfield SG, Norbury G, Humphries SE: Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet, 2010; 77: 572-580
76. Soutar AK, Naoumova RP: Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med, 2007; 4: 214-225
77. Muir LA, George PM, Laurie AD, Reid N, Whitehead L: Preventing cardiovascular disease: a review of the effectiveness of identifying the people with familial hypercholesterolaemia in New Zealand. N Z Med J, 2010; 123: 97-102
78. Hopkins, PN, Toth, PP, Ballantyne, CM, Rader, DJ: Familial Hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol, 2011; 5: S9-S17
79. Humphries SE, Norbury G, Leigh S, Hadfield SG, Nair D: What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia ? Curr Opin Lipidol, 2008; 19: 362-368
80. Lombardi MP, Redeker EJW, van Gent DHM, Smeele KL, Weederstein R, Mannens MM: Molecular genetic testing for familial hypercholesterolaemia in the Netherlands: a stepwise screening strategy enhances the mutation detection rate. Genet Test, 2006; 10: 77-84
81. National Institute for Health and Clinical Excellence, The National Collaborating Centre for Primary Care. NICE clinical guideline 71: identification and management of familial hypercholesterolaemia; 2008
82. Watts GF, van Bockxmeer FM, Bates T, Burnett JR, Juniper A, O’Leary P: A new model of care for familial hypercholesterolaemia from Western Australia: closing a major gap in preventive cardiology. Heart Lung Circ, 2010; 19: 419-422
83. Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, Gaunt TR, Pallas J, Lovering R, Li K, Casas JP, Sofat R, Kumari M, Rodriguez S, Johnson T, Newhouse SJ, Dominiczak A, Samani NJ, Caulfield M, Sever P, Stanton A, Shields DC, Padmanabhan S, Melander O, Hastie C, Delles C, Ebrahim S, Marmot MG, Smith GD, Lawlor DA, Munroe PB, Day IN, Kivimaki M, Whittaker J, Humphries SE, Hingorani AD for the ASCOT investigators; NORDIL investigators; and BRIGHT Consortium: Gene-centric association signals for lipids and apolipoproteins identified via the Human CVD Bead Chip. Am J Hum Genet, 2009; 85: 628-642
84. Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA, Harrison SC, Li K, Drenos F, Karpe F, Neil HA, Descamps OS, Langenberg C, Lench N, Kivimaki M, Whittaker J, Hingorani AD, Kumari M, Humphries SE: Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet, 2013; 381: 1293-1301
85. Brautbar A, Leary E, Rasmussen K, Wilson DP, Steiner RD, Virani S: Genetics of Familial Hypercholesterolemia. Curr Atheroscler Rep, 2015; 17: 20
86. Familial Hypercholesterolaemia Western Australia Program Committee. Model of care familial hypercholesterolaemia; 2008
87. Huijgen R, Kindt I, Verhoeven SB, Sijbrands EJ, Vissers MN, Kastelein JJ, Hutten BA: Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One, 2010; 5: e9220
88. Huijgen R, Vissers MN, Kindt I, Trip MD, de Groot E, Kastelein JJ, Hutten BA: Assessment of carotid atherosclerosis in normocholesterolemic individuals with proven mutations in the low-density lipoprotein receptor or apolipoprotein B genes. Circ Cardiovasc Genet, 2011; 4: 413-417
89. Civeira F: Guidelines for the diagnosis and management of heterozygous familial hypercholesterolaemia. Atherosclerosis, 2004; 173: 55-68
90. Datta BN, McDowell IF, Rees A: Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol, 2010; 21: 366-371
91. CLC-Bio. CLC Main Workbench. Aarhus, Denmark; 2011
92. University College London: Low-density lipoprotein receptor familial hypercholesterolemia database. London, United Kingdom; 2011 Available from: www.ucl.ac.uk/ldlr/Current/index.php?select db=LDLR
93. Usifo E, Leigh SE, Whittall RA, Lench N, Taylor A, Yeats C, Orengo CA, Martin AC, Celli J, Humphries SE: Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet, 2012; 76: 387-401
94. Etxebarria A, Benito-Vicente A, Alves AC, Ostolaza H, Bourbon M, Martin C: Advantages and versatility of fluorescence- based methodology to characterize the functionality of LDLR and class mutation assignment. PLoS One, 2014; 9: e112677
95. Langslet G, Ose L: Screening methods in the diagnosis and assessment of children and adolescents with familial hypercholesterolemia. Expert Rev Cardiovasc Ther, 2013; 11: 1061-1066
96. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA: Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol. Assess, 2000; 4: 1-123
97. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, Ziajka PE: Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol, 2011; (Suppl. 5): S1-S8
98. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics, 2011; 128 (Suppl. 5), S213-S256
99. Kusters DM, de Beaufort C, Widhalm K, Guardamagna O, Bratina N, Ose L, Wiegman A: Paediatric screening for hypercholesterolaemia in Europe. Arch Dis Child, 2012; 97: 272-276
100. Claassen L, Henneman L, Kindt I, Marteau TM, Timmermans DRM: Perceived risk and representations of cardiovascular disease and preventive behaviour in people diagnosed with familial hypercholesterolemia. J Health Psychol, 2010; 15: 33-43
101. Meulenkamp TM, Tibben A, Mollema ED, van Langen IM, Wiegman A, de Wert GM, de Beaufort ID, Wilde AAM, Smets EMA: Predictive genetic testing for cardiovascular diseases: impact on carrier children. Am J Med Genet A, 2008; A 146A, 3136-3146
102. de Jongh S, Kerckhoffs MC, Grootenhuis MA, Bakker HD, Heymans HS, Last BF: Quality of life, anxiety and concerns among statin-treated children with familial hypercholesterolaemia and their parents. Acta Paediatr, 2003; 92: 1096-1101
103. Leren TP: Cascade genetic screening for familial hypercholesterolemia. Clin Genet, 2004; 66: 483-487
104. Marteau T, Senior V, Humphries SE, Bobrow M, Cranston T, Crook MA, Day L, Fernandez M, Horne R, Iversen A, Jackson Z, Lynas J, Middleton-Price H, Savine R, Sikorski J, Watson M, Weinman J, Wierzbicki AS, Wray R; Genetic Risk Assessment for FH Trial Study Group: Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am J Med Genet, 2004; 128A: 285-293
105. van Maarle MC, Stouthard MEA, Bonsel GJ: Quality of life in a family based genetic cascade screening programme for familial hypercholesterolaemia: a longitudinal study among participants. J Med Genet, 2003; 40: e3-e
106. Versmissen J, Oosterveer DM, Yazdanpanah M, Deh-ghan A, Hólm H, Erdman J, Aulchenko YS, Thorleifsson G, Schunkert H, Huijgen R, Vongpromek R, Uitterlinden AG, Defesche JC, van Duijn CM, Mulder M, Dadd T, Karlsson HD, Ordovas J, Kindt I, Jarman A, Hofman A, van Vark-van der Zee L, Blommesteijn-Touw AC, Kwekkeboom J, Liem AH, van der Ouderaa FJ, Calandra S, Bertolini S, Averna M, Langslet G, Ose L, Ros E, Almagro F, de Leeuw PW, Civeira F, Masana L, Pintó X, Simoons ML, Schinkel AF, Green MR, Zwinderman AH, Johnson KJ, Schaefer A, Neil A, Witteman JC, Humphries SE, Kastelein JJ, Sijbrands EJ: Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach. Eur J Hum Genet, 2015; 23: 381-387
107. Lloyd-Jones DM: Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation, 2010; 121: 1768-1777